← Back
Data updated: Mar 10, 2026
EMERGE BIOSCIENCE
CardiovascularRespiratory
EMERGE BIOSCIENCE is a generic drug manufacturer focused on Cardiovascular, Respiratory.
2018
Since
4
Drugs
-
Trials
18
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
HEPARIN SODIUM 2026-02-20
Labeling
HEPARIN SODIUM 2026-02-20
Labeling
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2026-01-07
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2025-11-25
Labeling
HEPARIN SODIUM 2025-09-24
Labeling
HEPARIN SODIUM 2025-05-27
Labeling
HEPARIN SODIUM 2025-05-27
Labeling
HEPARIN SODIUM 2025-04-09
Labeling
HEPARIN SODIUM 2025-02-04
Labeling
HEPARIN SODIUM 2024-10-24
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 50%
2 drugs
Respiratory 50%
2 drugs
Pipeline Strength Pro
Loading...
Discontinued (2)
Company Info
- First Approval
- 2018-12-14
- Latest
- 2026-02-20
- Applications
- 7